A recent preclinical study using a mouse model of type 2 diabetes showed that a combination of the SGLT-2 inhibitor ipragliflozin plus pioglitazone significantly improved multiple NASH parameters, including hyperglycemia, insulin resistance, hyperlipidemia and liver injury (hepatic steatosis and fibrosis). This evidence concerns the gene SLC5A2 and fatty liver disease.